C520 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA sustained ~60% gross margin provides durable earnings leverage as revenue grows. High product margins give Enovis flexibility to fund R&D, support integration of acquisitions, and absorb some cost inflation while aiming to convert improving top-line into durable operating profit over the medium term.
Recon Segment Leadership & InnovationRecon's consistent outperformance (U.S. Recon organic growth +8%, extremities +10%) plus new systems (Nebula, ARG) and Arvis adoption create sustainable competitive advantages. Momentum in ASCs and instrument set rollouts increases procedure share, recurring instrumentation revenue, and long-term market penetration.
Improving Cash Generation And Balance SheetPositive and growing free cash flow, together with materially lower leverage versus 2024–2025, enhances financial flexibility. A >25% FCF conversion target supports reinvestment in Recon, disciplined CapEx, debt reduction or shareholder returns and reduces refinancing risk over the coming 2–6 months.
Bears Say
Severe Operating And Net LossesThe swing to very large operating losses and deep negative net margins undermines return metrics and implies the cost base currently outstrips revenue. Until structural cost control or profitable scale is sustained, negative earnings will constrain reinvestment, credit metrics, and long-term investor confidence.
Tariff And Geographic ExposureOngoing tariffs and regional disruptions create persistent margin pressure and revenue volatility. $4M of recurring tariff costs and multi‑month Middle East exposure can erode adjusted margins and make forward forecasting harder, particularly for P&R categories with lower organic growth.
Non-GAAP Comparability Reduced By SEC-driven ChangeThe SEC-driven change to exclude inventory step-up adjustments reduces historical non‑GAAP comparability and complicates trend analysis of adjusted margins. This structural reporting shift raises transparency and modeling challenges and may affect stakeholder assessment of recurring profitability.
Enovis News
C520 FAQ
What was Enovis Corporation’s price range in the past 12 months?
Currently, no data Available
What is Enovis Corporation’s market cap?
Enovis Corporation’s market cap is CHF1.26B.
When is Enovis Corporation’s upcoming earnings report date?
Enovis Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Enovis Corporation’s earnings last quarter?
Enovis Corporation released its earnings results on May 07, 2026. The company reported $0.724 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.063.
Is Enovis Corporation overvalued?
According to Wall Street analysts Enovis Corporation’s price is currently Undervalued.
Does Enovis Corporation pay dividends?
Enovis Corporation does not currently pay dividends.
What is Enovis Corporation’s EPS estimate?
Enovis Corporation’s EPS estimate is 0.69.
How many shares outstanding does Enovis Corporation have?
Enovis Corporation has 57,562,603 shares outstanding.
What happened to Enovis Corporation’s price movement after its last earnings report?
Enovis Corporation reported an EPS of $0.724 in its last earnings report, beating expectations of $0.66. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enovis Corporation?
Currently, no hedge funds are holding shares in CH:C520
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF32.31 (― Downside)
CHF32.31 (― Downside)
Insider Transactions
Bought Shares
Worth CHF74.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Enovis Corporation
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
C520 Stock 12 Month Forecast
Average Price Target
$32.31